Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration

Regulatory Peptides

Volumn 140, Issue 1-2, 2007, Pages 74-80

  Shin, Beom Soo ^a   Kim, Chul Hwan ^a   Lee, Min Nyung ^b   Hur, Man Wook ^b   Lee, Kang Choon ^a   Youn, Yu Seok ^a   Yoo, Sun Dong ^a  

^a Sungkyunkwan University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Bioavailability; GST TatdMt; Obesity; Pharmacokinetics; Tat; Tissue distribution

Indexed keywords

GLUTATHIONE S TRANSFERASE TATDMT PROTEIN IODINE 125; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG POTENCY; DRUG TISSUE LEVEL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; ANIMAL; GENETICS; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TISSUE DISTRIBUTION;

RATTUS;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; GENE PRODUCTS, TAT; GLUTATHIONE TRANSFERASE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IODINE RADIOISOTOPES; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33847226334     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.11.013     Document Type: Article

References (15)

1. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
2. Mann D.A., and Frankel A.D. Endocytosis and targeting of exogenous HIV-1 tat protein. EMBO J 10 (1991) 1730-1739
3. Kang H., Delong R., Fisher M.H., and Juliano R.L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22 (2005) 2099-2106
4. Kida S., Maeda M., Hojo K., Eto Y., Gao J., Kurachi S., Mizuguchi H., Hayakawa T., Mayumi T., Nakagawa S., and Kawasaki K. Design and synthesis of a Tat-related gene transporter: a tool for carrying the adenovirus vector into cells. Bioorg Med Chem Lett 16 (2006) 743-745
5. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
6. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., and Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91 (1994) 664-668
7. Lee H.J., and Pardridge W.M. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12 (2001) 995-999
8. Begley R., Liron T., Baryza J., and Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun 318 (2004) 949-954
9. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "Is the Trojan horse too wild to go only to Tory?". J Contemp Relig 109 (2005) 77-85
10. Brooks H., Lebleu B., and Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57 (2005) 559-577
11. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 57 (2005) 547-558
12. Shin B.S., Kim C.H., Jun Y.S., Park E.H., Hur M.W., Lee K.C., Yoon Y.S., Lee M.N., and Yoo S.D. Dose-linear pharmacokinetics, tissue distribution, and excretion of a recombinant fusion protein 125I-GST-TatdMt possessing potent anti-obesity activity. Regulatory Pept 129 (2005) 25-30
13. Hur MW, Lee DK. Anti-obesity polypeptides. US patent (pending) #10/475,688.
14. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membranes and accumulates in the cell nucleus. J Biol Chem 272 (1997) 16010-16017
15. Ezhevsky S.A., Nagahara H., Vocero-Akbani A.M., Gius D.R., Wei M.C., and Dowdy S.F. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A 94 (1997) 10699-10704